STAT+: Sutro Bio joins biotech’s zombie army. When will this insanity end?
Why Sutro Biopharma, a company seeking to develop its own cancer drugs, is adding to biotech’s zombie problem, STAT's Adam Feuerstein writes.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The newsletter was supposed to be on hiatus this week, but as they say, a dark event pulled me back in.
A zombie event.
